Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy
Purpose: To evaluate efficacy of eplerenone therapy vs. observation on resolution of subretinal fluid (SRF) in patients with acute and chronic central serous chorioretinopathy (CSCR) in routine clinical practice.Methods: Retrospective comparative case series of eyes diagnosed with CSCR treated with...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-05-01
|
| Series: | Frontiers in Pharmacology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fphar.2021.675295/full |
| _version_ | 1818736336244310016 |
|---|---|
| author | Katrin Fasler Katrin Fasler Jeanne M. Gunzinger Jeanne M. Gunzinger Daniel Barthelmes Daniel Barthelmes Daniel Barthelmes Sandrine A. Zweifel Sandrine A. Zweifel |
| author_facet | Katrin Fasler Katrin Fasler Jeanne M. Gunzinger Jeanne M. Gunzinger Daniel Barthelmes Daniel Barthelmes Daniel Barthelmes Sandrine A. Zweifel Sandrine A. Zweifel |
| author_sort | Katrin Fasler |
| collection | DOAJ |
| description | Purpose: To evaluate efficacy of eplerenone therapy vs. observation on resolution of subretinal fluid (SRF) in patients with acute and chronic central serous chorioretinopathy (CSCR) in routine clinical practice.Methods: Retrospective comparative case series of eyes diagnosed with CSCR treated with eplerenone or observation. Primary outcome measure was maximum height of SRF at 12 months. Secondary outcome was percentage of eyes with complete resolution of SRF, percentage of eyes with reduction of SRF ≥50%, and best corrected visual acuity (VA) at 12 months. Separate analysis was conducted for eyes with acute and chronic CSCR.Results: Sixty-eight eyes of 60 patients (82% male) were included. Eleven of the 38 eyes with acute CSCR, and seven of the 30 eyes with chronic CSCR, received eplerenone. Subretinal fluid decreased from baseline to 12 months in acute (287 ± 221 to 31 ± 63 µm) and chronic (148 ± 134 to 40 ± 42 µm) CSCR. Kaplan-Meier curves were similar for treated and observed eyes and COX regression analysis did not show a significant difference in SRF resolution in treated vs. observed eyes (p = 0.6 for acute, p = 0.2 for chronic CSCR).Conclusion: This routine clinical practice outcome study did not show evidence of efficacy of eplerenone on resolution of SRF in acute nor chronic CSCR. |
| first_indexed | 2024-12-18T00:35:32Z |
| format | Article |
| id | doaj.art-5b00d771b9b44ee994d7c340b2730f2c |
| institution | Directory Open Access Journal |
| issn | 1663-9812 |
| language | English |
| last_indexed | 2024-12-18T00:35:32Z |
| publishDate | 2021-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Pharmacology |
| spelling | doaj.art-5b00d771b9b44ee994d7c340b2730f2c2022-12-21T21:27:01ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122021-05-011210.3389/fphar.2021.675295675295Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous ChorioretinopathyKatrin Fasler0Katrin Fasler1Jeanne M. Gunzinger2Jeanne M. Gunzinger3Daniel Barthelmes4Daniel Barthelmes5Daniel Barthelmes6Sandrine A. Zweifel7Sandrine A. Zweifel8Department of Ophthalmology, University Hospital Zurich, Zurich, SwitzerlandUniversity of Zurich, Zurich, SwitzerlandDepartment of Ophthalmology, University Hospital Zurich, Zurich, SwitzerlandUniversity of Zurich, Zurich, SwitzerlandDepartment of Ophthalmology, University Hospital Zurich, Zurich, SwitzerlandUniversity of Zurich, Zurich, SwitzerlandSave Sight Institute, The University of Sydney, Sydney, NSW, AustraliaDepartment of Ophthalmology, University Hospital Zurich, Zurich, SwitzerlandUniversity of Zurich, Zurich, SwitzerlandPurpose: To evaluate efficacy of eplerenone therapy vs. observation on resolution of subretinal fluid (SRF) in patients with acute and chronic central serous chorioretinopathy (CSCR) in routine clinical practice.Methods: Retrospective comparative case series of eyes diagnosed with CSCR treated with eplerenone or observation. Primary outcome measure was maximum height of SRF at 12 months. Secondary outcome was percentage of eyes with complete resolution of SRF, percentage of eyes with reduction of SRF ≥50%, and best corrected visual acuity (VA) at 12 months. Separate analysis was conducted for eyes with acute and chronic CSCR.Results: Sixty-eight eyes of 60 patients (82% male) were included. Eleven of the 38 eyes with acute CSCR, and seven of the 30 eyes with chronic CSCR, received eplerenone. Subretinal fluid decreased from baseline to 12 months in acute (287 ± 221 to 31 ± 63 µm) and chronic (148 ± 134 to 40 ± 42 µm) CSCR. Kaplan-Meier curves were similar for treated and observed eyes and COX regression analysis did not show a significant difference in SRF resolution in treated vs. observed eyes (p = 0.6 for acute, p = 0.2 for chronic CSCR).Conclusion: This routine clinical practice outcome study did not show evidence of efficacy of eplerenone on resolution of SRF in acute nor chronic CSCR.https://www.frontiersin.org/articles/10.3389/fphar.2021.675295/fullaldosterone antagonistscentral serous chorioretinopathyeplerenonemedical retinaretinal disease |
| spellingShingle | Katrin Fasler Katrin Fasler Jeanne M. Gunzinger Jeanne M. Gunzinger Daniel Barthelmes Daniel Barthelmes Daniel Barthelmes Sandrine A. Zweifel Sandrine A. Zweifel Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy Frontiers in Pharmacology aldosterone antagonists central serous chorioretinopathy eplerenone medical retina retinal disease |
| title | Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy |
| title_full | Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy |
| title_fullStr | Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy |
| title_full_unstemmed | Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy |
| title_short | Routine Clinical Practice Treatment Outcomes of Eplerenone in Acute and Chronic Central Serous Chorioretinopathy |
| title_sort | routine clinical practice treatment outcomes of eplerenone in acute and chronic central serous chorioretinopathy |
| topic | aldosterone antagonists central serous chorioretinopathy eplerenone medical retina retinal disease |
| url | https://www.frontiersin.org/articles/10.3389/fphar.2021.675295/full |
| work_keys_str_mv | AT katrinfasler routineclinicalpracticetreatmentoutcomesofeplerenoneinacuteandchroniccentralserouschorioretinopathy AT katrinfasler routineclinicalpracticetreatmentoutcomesofeplerenoneinacuteandchroniccentralserouschorioretinopathy AT jeannemgunzinger routineclinicalpracticetreatmentoutcomesofeplerenoneinacuteandchroniccentralserouschorioretinopathy AT jeannemgunzinger routineclinicalpracticetreatmentoutcomesofeplerenoneinacuteandchroniccentralserouschorioretinopathy AT danielbarthelmes routineclinicalpracticetreatmentoutcomesofeplerenoneinacuteandchroniccentralserouschorioretinopathy AT danielbarthelmes routineclinicalpracticetreatmentoutcomesofeplerenoneinacuteandchroniccentralserouschorioretinopathy AT danielbarthelmes routineclinicalpracticetreatmentoutcomesofeplerenoneinacuteandchroniccentralserouschorioretinopathy AT sandrineazweifel routineclinicalpracticetreatmentoutcomesofeplerenoneinacuteandchroniccentralserouschorioretinopathy AT sandrineazweifel routineclinicalpracticetreatmentoutcomesofeplerenoneinacuteandchroniccentralserouschorioretinopathy |